Mon, Dec 29, 2014, 12:20 AM EST - U.S. Markets open in 9 hrs 10 mins

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

atlman79 2 posts  |  Last Activity: Nov 11, 2014 9:56 AM Member since: Mar 7, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Down 4%

    by gordongeico Nov 10, 2014 8:24 AM
    atlman79 atlman79 Nov 11, 2014 9:56 AM Flag

    ummm....no!! ROFLMAO at paid bashers lookin clueless!!

  • tripe from their mom's basement day in and day out for a nickel a post??? Or this guy...... Dr Joseph Kim was appointed president and CEO of Inovio Pharmaceuticals in June 2009. Dr. Kim cofounded VGX Pharmaceuticals, a synthetic vaccine company, in 2000, to develop intellectual property related to immunotherapeutics licensed from the University of Pennsylvania. He led that company for nine years and acquired Inovio Biomedical in 2009 to form Inovio Pharmaceuticals. Previously, Dr. Kim was a senior vaccine developer at Merck & Co., where he successfully led efforts in manufacturing and process development for several FDA-approved products for hepatitis, and developmental vaccines and therapeutics for HIV/AIDS. Dr. Kim earned a bachelor’s degree in chemical engineering and economics from the Massachusetts Institute of Technology, where he was a U.S. Senate Honors Scholar. He holds a Ph.D. in biochemical engineering from the University of Pennsylvania, and a master’s degree in business administration (finance) from the Wharton School. Dr. Kim has published more than 100 peer-reviewed scientific papers, holds numerous patents and sits on several editorial boards and review panels.???????

    Choice is yours!!!!!!!

INO
9.36+0.25(+2.74%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.